相似文献
1
Development of a histone deacetylase 6 inhibitor and its biological effects.
Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15704-9. doi: 10.1073/pnas.1313893110. Epub 2013 Sep 10.
2
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107. Epub 2010 Oct 29.
3
Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12005-10. doi: 10.1073/pnas.1515882112. Epub 2015 Sep 14.
4
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3.
5
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.
6
Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition.
Molecules. 2018 Feb 2;23(2):321. doi: 10.3390/molecules23020321.
7
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
J Med Chem. 2016 Feb 25;59(4):1545-55. doi: 10.1021/acs.jmedchem.5b01493. Epub 2015 Dec 22.
8
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.
9
Discovery of the first histone deacetylase 6/8 dual inhibitors.
J Med Chem. 2013 Jun 13;56(11):4816-20. doi: 10.1021/jm400390r. Epub 2013 May 29.
10
The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3254-3258. doi: 10.1016/j.bmcl.2017.06.033. Epub 2017 Jun 13.
引用本文的文献
1
Protein domain movement involved in binding of belinostat and HPOB as inhibitors of histone deacetylase 6 (HDAC6): a hybrid automated-interactive docking study.
J Comput Aided Mol Des. 2025 Jul 15;39(1):52. doi: 10.1007/s10822-025-00636-x.
2
Colon cancer cells evade drug action by enhancing drug metabolism.
Oncogene. 2025 Jul 10. doi: 10.1038/s41388-025-03472-3.
3
Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer.
Nat Cancer. 2024 Nov;5(11):1622-1640. doi: 10.1038/s43018-024-00816-y. Epub 2024 Aug 28.
4
Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism.
bioRxiv. 2023 Dec 23:2023.12.21.572817. doi: 10.1101/2023.12.21.572817.
5
HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation.
Front Immunol. 2023 Jul 21;14:1168848. doi: 10.3389/fimmu.2023.1168848. eCollection 2023.
6
Targeting histone deacetylases for cancer therapy: Trends and challenges.
Acta Pharm Sin B. 2023 Jun;13(6):2425-2463. doi: 10.1016/j.apsb.2023.02.007. Epub 2023 Feb 18.
7
Recent advancement of HDAC inhibitors against breast cancer.
Med Oncol. 2023 Jun 9;40(7):201. doi: 10.1007/s12032-023-02058-x.
8
Histone deacetylase 6 plays an important role in TGF-β-induced murine Treg cell differentiation by regulating cell proliferation.
Sci Rep. 2022 Dec 29;12(1):22550. doi: 10.1038/s41598-022-27230-7.
9
Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells.
Cancers (Basel). 2022 Dec 6;14(23):6014. doi: 10.3390/cancers14236014.
10
Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Mol Divers. 2023 Oct;27(5):2053-2071. doi: 10.1007/s11030-022-10540-3. Epub 2022 Oct 10.
本文引用的文献
1
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
FEBS J. 2013 Feb;280(3):775-93. doi: 10.1111/febs.12079. Epub 2012 Dec 20.
2
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
J Med Chem. 2012 Nov 26;55(22):9891-9. doi: 10.1021/jm301098e. Epub 2012 Oct 23.
3
Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.
PLoS One. 2012;7(9):e44265. doi: 10.1371/journal.pone.0044265. Epub 2012 Sep 5.
4
Development and therapeutic impact of HDAC6-selective inhibitors.
Biochem Pharmacol. 2012 Sep 15;84(6):756-65. doi: 10.1016/j.bcp.2012.06.014. Epub 2012 Jun 21.
5
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19.
6
A novel class of small molecule inhibitors of HDAC6.
ACS Chem Biol. 2012 Feb 17;7(2):331-9. doi: 10.1021/cb200134p. Epub 2011 Nov 11.
7
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107. Epub 2010 Oct 29.
8
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44. doi: 10.1073/pnas.1008522107. Epub 2010 Aug 2.
9
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.
J Am Chem Soc. 2010 Aug 11;132(31):10842-6. doi: 10.1021/ja102758v.
10
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):717-25. doi: 10.1016/j.bbagrm.2010.05.008. Epub 2010 Jun 8.
Zotero 插件